Medexus Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MEDXF research report →
About the company
Medexus Pharmaceuticals Inc. is a specialized pharmaceutical firm conducting operations across both Canada and the United States. The company's therapeutic focus spans several critical domains, including cancer treatment (oncology), blood disorders (hematology), joint and muscle conditions (rheumatology), autoimmune disorders, and allergic reactions.
- CEO
- Kenneth d'Entremont
- IPO
- 2017
- Employees
- 82
- HQ
- Bolton, ON, CA
Price Chart
- Market Cap
- $114.61M
- P/E
- -51.41
- P/S
- 1.15
- P/B
- 2.37
- EV/EBITDA
- 10.35
- Div Yield
- 0.00%
- Gross Margin
- 54.78%
- Op Margin
- 5.87%
- Net Margin
- -2.37%
- ROE
- -4.55%
- ROIC
- 6.08%
- Revenue
- $99.33M · -8.31%
- Net Income
- $-2,394,000 · -206.54%
- EPS
- $-0.07 · -183.23%
- Op Income
- $5.83M
- FCF YoY
- -82.54%
- 52W High
- $3.68
- 52W Low
- $1.80
- 50D MA
- $2.92
- 200D MA
- $2.32
- Beta
- 1.81
- Avg Volume
- 13.83K
Get TickerSpark's AI analysis on MEDXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MEDXF coverage
Recent articles, reports, and earnings notes.
No research on MEDXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MEDXF report →Similar companies
Peers in the same neighborhood.